Review of basic concepts of cell kinetics as applied to brain tumors.
The authors review and discuss the basic concepts of cell kinetics as applied to brain tumors. Uncontrolled growth of a neoplasm represents an expanding tumor cell population. Four growth parameters characterize the behavior of a neoplastic population: cell cycle time, growth fraction, tumor doubling time, and cell loss. The concept of provisionally nondividing cells explains the disparity between cell cycle time and tumor doubling time. Human gliomas, like many non-neural solid tumors, contain variable proportions of actively proliferating and nonproliferating tumor cells; this ratio is expressed by the growth fraction. The major kinetic difference between glioblastomas and differentiated astrocytomas resides in their respective growth fractions, in all likelihood an inherent biological characteristic of each tumor. Glioblastoma proliferates at a rapid rate, and only a high rate of cell loss prevents this tumor from doubling its volume in less than 1 week. The selection of drugs and design of drug schedules for treatment of glioblastomas should be made with the knowledge that 60% to 70% of the cells in this tumor are resting (nonproliferating). If experience with other solid tumors is any guide, judicious selection and combined use of drugs according to kinetically sound schedules will produce more effective chemotherapy of brain tumors.
D000477:Alkylating Agents / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000963:Antimetabolites / Q000494:pharmacology; D001254:Astrocytoma / Q000188:drug therapy / Q000473:pathology; D001921:Brain / Q000473:pathology; D001932:Brain Neoplasms / Q000473:pathology*; D002470:Cell Survival; D004273:DNA, Neoplasm / Q000096:biosynthesis; D005910:Glioma / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007700:Kinetics; D015122:Mercaptopurine / Q000627:therapeutic use; D008938:Mitosis; D009362:Neoplasm Metastasis; D011239:Prednisolone / Q000627:therapeutic use; D012334:RNA, Neoplasm / Q000096:biosynthesis; D012075:Remission, Spontaneous; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
D000477:Alkylating Agents; D000900:Anti-Bacterial Agents; D000963:Antimetabolites; D004273:DNA, Neoplasm; D012334:RNA, Neoplasm; D014750:Vincristine; D011239:Prednisolone; D015122:Mercaptopurine